1887

Abstract

Thrombin has been demonstrated to be involved in several viral diseases including human metapneumovirus (hMPV) infections. We previously showed that immediate administration of thrombin inhibitor argatroban post-infection protected mice against hMPV disease. This current work aims at determining whether warfarin and heparin, two other anticoagulants inhibiting thrombin formation and activities, may also be used for treatment against hMPV in vivo. We found that immediate injections of argatroban, warfarin or heparin after virus challenge protected mice against hMPV infection, as evidenced by decreased or no mortality, less weight loss, reduced viral load and attenuated inflammation. However, delayed treatments starting 1 day post-infection with argatroban or warfarin almost did not impact the survival whereas delayed treatment with heparin induced an increased mortality during infection. Moreover, these treatments also did not reduce weight loss, viral replication and inflammation. In agreement with these results, thrombin generation was decreased upon immediate anticoagulant treatments but was unaltered upon delayed treatments. Thus, thrombin generation occurs at the onset of hMPV infection and thrombin inhibition may be only useful for the treatment of this disease when initiated in the early stage. In this case, heparin is not recommended because of its reduced efficacy on mortality in infected mice whereas argatroban and warfarin appear as safe and effective drugs for the treatment of hMPV disease. The antiviral and anti-inflammatory effects of argatroban occur via thrombin-dependent pathways whereas the mechanisms by which warfarin exerts its beneficial effects against hMPV infection were not elucidated and need to be further studied.

Keyword(s): argatroban , heparin , hMPV , PAR1 , thrombin and warfarin
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001135
2018-08-10
2019-09-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/99/10/1367.html?itemId=/content/journal/jgv/10.1099/jgv.0.001135&mimeType=html&fmt=ahah

References

  1. Afonso CL, Amarasinghe GK, Bányai K, Bào Y, Basler CF et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol 2016;161:2351–2360 [CrossRef][PubMed]
    [Google Scholar]
  2. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7:719–724 [CrossRef][PubMed]
    [Google Scholar]
  3. Yang CF, Wang CK, Tollefson SJ, Piyaratna R, Lintao LD et al. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years. Virol J 2009;6:138 [CrossRef][PubMed]
    [Google Scholar]
  4. Aberle JH, Aberle SW, Redlberger-Fritz M, Sandhofer MJ, Popow-Kraupp T. Human metapneumovirus subgroup changes and seasonality during epidemics. Pediatr Infect Dis J 2010;29:1–1018 [CrossRef][PubMed]
    [Google Scholar]
  5. Esposito S, Mastrolia MV. Metapneumovirus infections and respiratory complications. Semin Respir Crit Care Med 2016;37:512–521 [CrossRef][PubMed]
    [Google Scholar]
  6. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009;108:1447–1452 [CrossRef][PubMed]
    [Google Scholar]
  7. VB, Riteau B, Alessi MC, Couture C, Jandrot-Perrus M et al. Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections. Br J Pharmacol 2018;175:388–403 [CrossRef][PubMed]
    [Google Scholar]
  8. Dhillon S. Argatroban: a review of its use in the management of heparin-induced thrombocytopenia. Am J Cardiovasc Drugs 2009;9:261–282 [CrossRef][PubMed]
    [Google Scholar]
  9. Young G. Anticoagulants in children and adolescents. Hematology Am Soc Hematol Educ Program 2015;2015:111–116 [CrossRef][PubMed]
    [Google Scholar]
  10. Yee DL, O'Brien SH, Young G. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet 2013;52:967–980 [CrossRef][PubMed]
    [Google Scholar]
  11. Cook BW. Anticoagulation management. Semin Intervent Radiol 2010;27:360–367 [CrossRef][PubMed]
    [Google Scholar]
  12. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114:445S–469[PubMed]
    [Google Scholar]
  13. Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proc 2001;14:305–306 [CrossRef]
    [Google Scholar]
  14. Young G, Male C, van Ommen CH. Anticoagulation in children: making the most of little patients and little evidence. Blood Cells Mol Dis 2017;67:48–53 [CrossRef][PubMed]
    [Google Scholar]
  15. Hamelin ME, Yim K, Kuhn KH, Cragin RP, Boukhvalova M et al. Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats. J Virol 2005;79:8894–8903 [CrossRef][PubMed]
    [Google Scholar]
  16. Kanade GD, Pingale KD, Karpe YA. Activities of thrombin and factor Xa are essential for replication of hepatitis E virus and are possibly implicated in ORF1 polyprotein processing. J Virol 2018;92:e01853-17 [CrossRef][PubMed]
    [Google Scholar]
  17. Antoniak S, Owens AP, Baunacke M, Williams JC, Lee RD et al. PAR-1 contributes to the innate immune response during viral infection. J Clin Invest 2013;123:1310–1322 [CrossRef][PubMed]
    [Google Scholar]
  18. Sutherland MR, Friedman HM, Pryzdial EL. Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1. J Thromb Haemost 2007;5:1055–1061 [CrossRef][PubMed]
    [Google Scholar]
  19. Ling H, Xiao P, Usami O, Hattori T. Thrombin activates envelope glycoproteins of HIV type 1 and enhances fusion. Microbes Infect 2004;6:414–420 [CrossRef][PubMed]
    [Google Scholar]
  20. Scholz M, Vogel JU, Höver G, Kotchetkov R, Cinatl J et al. Thrombin stimulates IL-6 and IL-8 expression in cytomegalovirus-infected human retinal pigment epithelial cells. Int J Mol Med 2004;13:327–331 [CrossRef][PubMed]
    [Google Scholar]
  21. Khoufache K, Berri F, Nacken W, Vogel AB, Delenne M et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest 2013;123:206–214 [CrossRef][PubMed]
    [Google Scholar]
  22. VB, Schneider JG, Boergeling Y, Berri F, Ducatez M et al. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. Am J Respir Crit Care Med 2015;191:804–819 [CrossRef][PubMed]
    [Google Scholar]
  23. Keller TT, van der Sluijs KF, de Kruif MD, Gerdes VE, Meijers JC et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 2006;99:1261–1269 [CrossRef][PubMed]
    [Google Scholar]
  24. Schouten M, Sluijs KF, Gerlitz B, Grinnell BW, Roelofs JJ et al. Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study. Crit Care 2010;14:R65 [CrossRef][PubMed]
    [Google Scholar]
  25. Boilard E, Paré G, Rousseau M, Cloutier N, Dubuc I et al. Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation. Blood 2014;123:2854–2863 [CrossRef][PubMed]
    [Google Scholar]
  26. Feuillet F, Lina B, Rosa-Calatrava M, Boivin G. Ten years of human metapneumovirus research. J Clin Virol 2012;53:97–105 [CrossRef][PubMed]
    [Google Scholar]
  27. Jeske WP, Fareed J, Hoppensteadt DA, Lewis B, Walenga JM. Pharmacology of argatroban. Exp Rev Hematol 2010;3:527–539 [CrossRef]
    [Google Scholar]
  28. Wessler S, Gitel SN. Pharmacology of heparin and warfarin. J Am Coll Cardiol 1986;8:10B–20 [CrossRef][PubMed]
    [Google Scholar]
  29. Sundaram KS, Lev M. Warfarin administration reduces synthesis of sulfatides and other sphingolipids in mouse brain. J Lipid Res 1988;29:1475–1479[PubMed]
    [Google Scholar]
  30. Li Y, Sun JF, Cui X, Mani H, Danner RL et al. The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies. Crit Care Med 2011;39:1104–1112 [CrossRef][PubMed]
    [Google Scholar]
  31. Eichbaum FW, Slemer O, Zyngier SB. Anti-inflammatory effect of warfarin and vitamin K1. Naunyn Schmiedebergs Arch Pharmacol 1979;307:185–190 [CrossRef][PubMed]
    [Google Scholar]
  32. Ma L, Dorling A. The roles of thrombin and protease-activated receptors in inflammation. Semin Immunopathol 2012;34:63–72 [CrossRef][PubMed]
    [Google Scholar]
  33. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992;90:1614–1621 [CrossRef][PubMed]
    [Google Scholar]
  34. Kobayashi Y, Sakamoto Y, Shibasaki M, Kimura I, Matsuo H. Human alveolar macrophages synthesize endothelins by thrombin. J Immunol 1997;158:5442–5447[PubMed]
    [Google Scholar]
  35. Lin CC, Shih CH, Yang YL, Bien MY, Lin CH et al. Thrombin induces inducible nitric oxide synthase expression via the MAPK, MSK1, and NF-κB signaling pathways in alveolar macrophages. Eur J Pharmacol 2011;672:180–187 [CrossRef][PubMed]
    [Google Scholar]
  36. Kolli D, Gupta MR, Sbrana E, Velayutham TS, Chao H et al. Alveolar macrophages contribute to the pathogenesis of human metapneumovirus infection while protecting against respiratory syncytial virus infection. Am J Respir Cell Mol Biol 2014;51:502–515 [CrossRef][PubMed]
    [Google Scholar]
  37. Dubovi EJ, Geratz JD, Tidwell RR. Enhancement of respiratory syncytial virus-induced cytopathology by trypsin, thrombin, and plasmin. Infect Immun 1983;40:351–358[PubMed]
    [Google Scholar]
  38. Bourinbaiar AS, Tan X, Nagorny R. Inhibitory effect of coumarins on HIV-1 replication and cell-mediated or cell-free viral transmission. Acta Virol 1993;37:241–250[PubMed]
    [Google Scholar]
  39. Lin PH, Ke YY, Su CT, Shiao HY, Hsieh HP et al. Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway. J Virol 2011;85:9114–9126 [CrossRef][PubMed]
    [Google Scholar]
  40. Kater AP, Peppelenbosch MP, Brandjes DP, Lumbantobing M. Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction. Clin Diagn Lab Immunol 2002;9:1396–1397 [CrossRef][PubMed]
    [Google Scholar]
  41. Cross JV, Deak JC, Rich EA, Qian Y, Lewis M et al. Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. J Biol Chem 1999;274:31150–31154 [CrossRef][PubMed]
    [Google Scholar]
  42. Lin YL, Lei HY, Lin YS, Yeh TM, Chen SH et al. Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antiviral Res 2002;56:93–96 [CrossRef][PubMed]
    [Google Scholar]
  43. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J et al. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1988;85:6132–6136 [CrossRef][PubMed]
    [Google Scholar]
  44. Martínez I, Melero JA. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J Gen Virol 2000;81:2715–2722 [CrossRef][PubMed]
    [Google Scholar]
  45. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008;122:743–752 [CrossRef][PubMed]
    [Google Scholar]
  46. Fahey TJ, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG et al. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 1992;148:2764–2769[PubMed]
    [Google Scholar]
  47. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008;122:293–298 [CrossRef][PubMed]
    [Google Scholar]
  48. Krusat T, Streckert HJ. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 1997;142:1247–1254 [CrossRef][PubMed]
    [Google Scholar]
  49. Bourgeois C, Bour JB, Lidholt K, Gauthray C, Pothier P. Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro. J Virol 1998;72:7221–7227[PubMed]
    [Google Scholar]
  50. Visseren FL, Bouwman JJ, Bouter KP, Diepersloot RJ, de Groot PH et al. Procoagulant activity of endothelial cells after infection with respiratory viruses. Thromb Haemost 2000;84:319–324[PubMed]
    [Google Scholar]
  51. van Wissen M, Keller TT, van Gorp EC, Gerdes VE, Meijers JC et al. Acute respiratory tract infection leads to procoagulant changes in human subjects. J Thromb Haemost 2011;9:1432–1434 [CrossRef][PubMed]
    [Google Scholar]
  52. Dahlem P, van Aalderen WM, Bos AP. Pediatric acute lung injury. Paediatr Respir Rev 2007;8:348–362 [CrossRef][PubMed]
    [Google Scholar]
  53. Wilkesmann A, Schildgen O, Eis-Hübinger AM, Geikowski T, Glatzel T et al. Human metapneumovirus infections cause similar symptoms and clinical severity as respiratory syncytial virus infections. Eur J Pediatr 2006;165:467–475 [CrossRef][PubMed]
    [Google Scholar]
  54. Deffrasnes C, Hamelin ME, Prince GA, Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother 2008;52:279–287 [CrossRef][PubMed]
    [Google Scholar]
  55. Schildgen O, Simon A, Williams J. Animal models for human metapneumovirus (HMPV) infections. Vet Res 2007;38:117–126 [CrossRef][PubMed]
    [Google Scholar]
  56. Asanuma K, Wakabayashi H, Hayashi T, Okuyama N, Seto M et al. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology 2004;67:166–173 [CrossRef][PubMed]
    [Google Scholar]
  57. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88–96 [CrossRef][PubMed]
    [Google Scholar]
  58. Hu L, van der Hoogt CC, Espirito Santo SM, Out R, Kypreos KE et al. The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI. J Lipid Res 2008;49:1553–1561 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001135
Loading
/content/journal/jgv/10.1099/jgv.0.001135
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error